Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
about
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentA novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeysThe multiple facets of FcRn in immunity.Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Current progress in innovative engineered antibodies.Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.Target-independent variable region mediated effects on antibody clearance can be FcRn independent.The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.Nonspecificity in a nonimmune human scFv repertoire.Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries.A role for macromolecular crowding in off-target binding of therapeutic antibodies.Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
P2860
Q28082880-92B6B2CB-5D7E-40E9-8CE8-91F151F10CD2Q36211427-C475CFE8-B1B0-48B3-86D3-5947DDF0D5EBQ37141605-61B45C01-3B2E-460D-B745-B214C151E2DFQ38615385-3561D484-CF7E-480D-8024-681A11CED09AQ38821056-447076CE-634B-4C2F-8CE6-E7E8A9EDEBD3Q39277950-BFB940A3-6570-47F5-8199-4158CC470F38Q40077818-A99BDF1D-D153-4660-BF63-054FFB5C33EEQ40545249-209228E1-D0B3-4469-8B92-E5201A1D5805Q41416019-09406D50-70C4-4275-8B1E-165204D0D2A7Q42186438-9DD6F0A0-14AA-4833-82EB-A7B5A9CAC7F6Q42280835-49FB79F7-B1E8-4B47-A2FD-3FC8E60149E3Q47305620-4530EC43-C9B5-47A4-A6AD-70FAAE8142A2Q47853083-0CC1B6D5-90AB-440B-B47B-AF8F0B700C1DQ54979517-2A5ED06C-52CE-4BCE-8D91-B33BB562EE2A
P2860
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Balancing charge in the comple ...... improves the pharmacokinetics
@ast
Balancing charge in the comple ...... improves the pharmacokinetics
@en
type
label
Balancing charge in the comple ...... improves the pharmacokinetics
@ast
Balancing charge in the comple ...... improves the pharmacokinetics
@en
prefLabel
Balancing charge in the comple ...... improves the pharmacokinetics
@ast
Balancing charge in the comple ...... improves the pharmacokinetics
@en
P2093
P2860
P1476
Balancing charge in the comple ...... improves the pharmacokinetics
@en
P2093
Amita Datta-Mannan
Arunkumar Thangaraju
Derrick R Witcher
Donmienne Leung
Victor J Wroblewski
P2860
P304
P356
10.1080/19420862.2015.1016696
P577
2015-01-01T00:00:00Z